KYMR:NASDAQKymera Therapeutics, Inc. Analysis

Kymera Therapeutics (KYMR) trades at $81.46, below its 20‑day (≈$82.34) and 50‑day (≈$83.29) simple moving averages, with a neutral RSI (~47) and a bearish MACD signal. The stock sits near a technical support level around $76.9 and faces resistance near $89.5, while exhibiting high 30‑day volatility (~35%) and a beta above 1, indicating pronounced price swings. Fundamentally, the company reports rapid revenue growth of 55% to $51.5 M, ample cash of $650 M against $80 M of debt, but remains unprofitable with negative earnings, a price‑to‑sales ratio over 130, and a price‑to‑book of 4.2.
Analyst sentiment is very positive – 22 analysts rate the stock a “strong buy” with a median 12‑month target of $118, implying ~45% upside. Recent material news highlights continued progress in its STAT6 and IRAK4 degrader programs, Q1 earnings that lifted estimates, and a new coverage buy from Canaccord. However, a shareholder investigation and insider stock sales introduce corporate governance concerns that temper short‑term confidence.